IS-002 Phase 2 Prostate Cancer Study

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

May 21, 2024

Study Completion Date

May 23, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Administration of IS-002

Intravenous administration of IS-002 approximately 24 hours prior to surgery

DEVICE

Firefly fluorescent imaging

Near-infrared fluorescence imaging using Firefly technology will allow fluorescence imaging of IS-002

PROCEDURE

robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection

Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection

Trial Locations (4)

10065

MSKCC, New York

21287

Johns Hopkins, Baltimore

55905

Mayo Clinic, Rochester

94158

UCSF, San Francisco

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Intuitive Surgical

INDUSTRY

NCT05946603 - IS-002 Phase 2 Prostate Cancer Study | Biotech Hunter | Biotech Hunter